Promedior Closes $24.5M Series D
Promedior Inc., a biotech company developing therapeutics for the treatment of fibrosis, has closed its Series D round with $24.5 million, having added $3 million in new capital from Shire Strategic Investment Group. Other investors in the round include Fibrotec Ventures, Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group.
15 October 2012•3 mins read
